A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Gene Therapy

• Publication date

  2000-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.cgt.7700145PMID 10766353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

  1998cited by this paper
• Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery.

  1998influential reference
• Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.

  1998cited by this paper
• Antisense '97: A roundtable on the state of the industry

  1997cited by this paper
• Basis of Pulmonary Toxicity Associated with Cationic Lipid-Mediated Gene Transfer to the Mammalian Lung

  1997cited by this paper
• Stabilization of cationic liposome‐plasmid DNA complexes by polyamines and poly(ethylene glycol)‐phospholipid conjugates for efficient in vivo gene delivery

  1997cited by this paper
• Limitations of Cationic Liposomes for Antisense Oligonucleotide Delivery in Vivo

  1997cited by this paper
• Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells.

  1997cited by this paper
• P‐glycoprotein mediated multidrug resistance and its implications for pathology

  1997cited by this paper
• Improved DNA: liposome complexes for increased systemic delivery and gene expression

  1997influential reference
• Comparative Pharmacokinetics, Tissue Distribution, and Tumor Accumulation of Phosphorothioate, Phosphorodithioate, and Methylphosphonate Oligonucleotides in Nude Mice

  1997cited by this paper
• Antisense oligodeoxynucleotides as clinical therapeutic agents.

  1996cited by this paper
• Multidrug Resistance of Cancer Cells

  1996cited by this paper
• Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid

  1996cited by this paper
• Fate of cationic liposomes and their complex with oligonucleotide in vivo.

  1996cited by this paper
• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

  1996cited by this paper
• In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.

  1996cited by this paper
• Cationic lipide mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modulation of gene expression

  1996cited by this paper
• Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.

  1996influential reference
• Cationic lipid binding to DNA: characterization of complex formation.

  1996cited by this paper
• Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.

  1996cited by this paper
• Pharmacokinetics of Antisense Oligonucleotides

  1995cited by this paper
• P‐glycoprotein stability is affected by serum deprivation and high cell density in multidrug‐resistant cells

  1995cited by this paper
• Pharmacokinetics of long-circulating liposomes

  1995cited by this paper
• Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA.

  1995cited by this paper
• Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)

  1994cited by this paper
• Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.

  1994cited by this paper
• Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.

  1993cited by this paper
• Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

  1993cited by this paper
• Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.

  1993cited by this paper
• Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

  1993cited by this paper
• In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.

  1992cited by this paper
• Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo

  1992cited by this paper
• Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

  1992cited by this paper
• Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

  1992cited by this paper
• Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles.

  1991cited by this paper
• Preparation and characterization of a chimeric CD 19 monoclonal antibody

  1991cited by this paper
• Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.

  1991cited by this paper
• Pharmacokinetics of stealth versus conventional liposomes: effect of dose.

  1991cited by this paper
• The products of the mdr1a and mdr1b genes from multidrug resistant murine cells have similar degradation rates.

  1990cited by this paper
• Lipid composition is important for highly efficient target binding and retention of immunoliposomes.

  1990cited by this paper
• Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

  1990cited by this paper
• Iodo-Gen-mediated radioiodination of nucleic acids.

  1988cited by this paper
• Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration.

  1987cited by this paper
• Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

  1987influential reference
• 125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo.

  1984cited by this paper
• Liposome targeting in vivo: Problems and opportunities

  1983cited by this paper
• Cancer: Principles and Practice of Oncology

  1982cited by this paper
• Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes.

  1979cited by this paper
• Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation.

  1978cited by this paper
• Interaction of liposomes with blood plasma proteins.

  1976cited by this paper
• Iodination of nucleic acids in vitro.

  1971cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper
• Antisense Oligonucleotides as Therapeutic Agents Is the Bullet Really Magical ?

  year unknowncited by this paper

• The Landscape of Nanoparticle-based siRNA Delivery and Therapeutic Development.

  2024cites this paper
• Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids.

  2024cites this paper
• Targeted modulation of gene expression through receptor‐specific delivery of small interfering RNA peptide conjugates

  2024cites this paper
• Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications

  2023cites this paper
• siRNA Therapeutics and its Challenges: Recent Advances in Effective Delivery for Cancer Therapy

  2022cites this paper
• Viscous Core Liposomes Increase siRNA Encapsulation and Provides Gene Inhibition When Slightly Positively Charged

  2021cites this paper
• Fabrication of aptamer-guided siRNA loaded lipopolyplexes for gene silencing of notch 1 in MDA-mb-231 triple negative breast cancer cell line

  2021cites this paper
• Role of ATP-binding cassette transporters in cancer initiation and progression.

  2020cites this paper
• Recent advances in siRNA delivery mediated by lipid-based nanoparticles

  2020cites this paper
• Nanomaterials for Therapeutic RNA Delivery

  2020cites this paper
• Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications

  2019cites this paper
• An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma

  2019cites this paper
• A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer.

  2019cites this paper
• Liposomal Delivery Systems: Design Optimization and Current Applications.

  2017cites this paper
• Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward.

  2017cites this paper
• Optimized Ultrasound Conditions for Enhanced Sensitivity of Molecular Beacons in the Detection of MDR1 mRNA in Living Cells.

  2016cites this paper
• Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression.

  2015cites this paper
• Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE–/– Mice

  2015cites this paper
• Nanotechnology for Cancer Diagnostics and Therapy - An Update on Novel Molecular Players

  2014cites this paper
• Targeted lipid nanoparticles for antisense oligonucleotide delivery.

  2014cites this paper
• Next Generation Delivery System for Proteins and Genes of Therapeutic Purpose: Why and How?

  2014cites this paper
• Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.

  2014cites this paper
• Folate-Targeted Liposome Encapsulating Chitosan/Oligonucleotide Polyplexes for Tumor Targeting

  2014cites this paper
• Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.

  2013cites this paper
• Antibody-targeted immunoliposomes for cancer treatment.

  2013cites this paper
• P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.

  2013cites this paper
• Antibody-based Therapeutics for the Treatment of Human B cell Malignancies

  2013cites this paper
• PR_b functionalized stealth liposomes for targeted delivery to metastatic colon cancer.

  2013cites this paper
• Liposomal drug delivery systems: from concept to clinical applications.

  2013cites this paper
• Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics

  2012cites this paper
• Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs

  2012cites this paper
• Application of poly(ethylene glycol)–distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery

  2012cites this paper
• Liposome-Encapsulated Polyethylenimine/Oligonucleotide Polyplexes Prepared by Reverse-Phase Evaporation Technique

  2012cites this paper
• Human ABCG2: structure, function, and its role in multidrug resistance.

  2012cites this paper
• Contributions of TM5, ECL3 and TM6 of human BCRP to its oligomerization activities and transport functions

  2011cites this paper
• Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft

  2011cites this paper
• Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.

  2011cites this paper
• Delivery of Nucleic Acids and Gene Delivery

  2011cites this paper
• Nanoparticles: A Promising Modality in the Treatment of Sarcomas

  2011cites this paper
• Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes

  2010cites this paper
• Reversal of MDR1 Gene-Dependent Multidrug Resistance in HL60/HT9 Cells Using Short Hairpin RNA Expression Vectors

  2010cites this paper
• Oligonucleotide Based Liposomal Nanoparticles for Leukemia and Liver Cancer Therapy

  2010cites this paper
• Advances in synthetic siRNA delivery.

  2010cites this paper
• Targeted Delivery Systems for Oligonucleotide Therapeutics

  2009cites this paper
• Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.

  2009cites this paper
• Recent advances in tumor vasculature targeting using liposomal drug delivery systems

  2009cites this paper
• Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro.

  2009cites this paper
• Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting.

  2009cites this paper
• Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.

  2008cites this paper
• Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing.

  2008cites this paper
• Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.

  2007cites this paper
• Ligand-targeted liposomal therapies of neuroblastoma.

  2007cites this paper
• Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.

  2007cites this paper
• Überwindung der P-Glykoprotein (MDR1)-abhängigen Multidrugresistenz mittels RNA-Interferenz

  2007cites this paper
• Liposomal Formulations for Nucleic Acid Delivery

  2007cites this paper
• Evaluation of telomerase control elements and radiation-inducible Waf1 promoter for the enhancement of targeted radiotherapy in neuroblastoma cells

  2007cites this paper
• Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

  2006cites this paper
• Modulation unterschiedlicher Formen der Multidrug-Resistenz mittels eines Multitargetmultiribozymes

  2006cites this paper
• Complete Reversal of ABCG2-Depending Atypical Multidrug Resistance by RNA Interference in Human Carcinoma Cells

  2006cites this paper
• Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

  2006cites this paper
• Formulation and delivery issues for monoclonal antibody therapeutics.

  2006cites this paper
• Chemosensitization of carcinoma cells using epithelial cell adhesion molecule–targeted liposomal antisense against bcl-2/bcl-xL

  2006cites this paper
• Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.

  2006cites this paper
• MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.

  2006cites this paper
• Entrapment of small molecules and nucleic acid-based drugs in liposomes.

  2005cites this paper
• Liposomal drug delivery systems--clinical applications.

  2005cites this paper
• In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein

  2005cites this paper
• Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

  2005cites this paper
• Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.

  2005cites this paper
• RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.

  2005cites this paper
• Cell-Specific Targeting of Lipid-Based Carriers for ODN and DNA

  2005cites this paper
• Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells.

  2005cites this paper
• Development of efficient packaging method of oligodeoxynucleotides by a condensed nano particle in lipid envelope structure.

  2005cites this paper
• Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.

  2005cites this paper
• Lymphoproliferative disorders: prospects for gene therapy

  2005cites this paper
• Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by RNA interference

  2005cites this paper
• Advantages of liposomal delivery systems for anthracyclines.

  2004cites this paper
• High efficiency entrapment of antisense oligonucleotides in liposomes.

  2004cites this paper
• Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference

  2004cites this paper
• Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides.

  2004cites this paper
• Development of ligand-targeted liposomes for cancer therapy

  2004cites this paper
• Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

  2004cites this paper
• Targeted Delivery of Oncogene‐Selective Antisense Oligonucleotides in Neuroectodermal Tumors: Therapeutic Implications

  2004cites this paper
• Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)

  2003cites this paper
• Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.

  2003cites this paper
• Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems.

  2003cites this paper
• Drug-delivery systems for local anesthetics: therapeutic applications.

  2003cites this paper
• Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.

  2003cites this paper
• Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

  2003cites this paper
• Massive and Selective Delivery of Lipid-Coated Cationic Lipoplexes of Oligonucleotides Targeted in Vivo to Hepatic Endothelial Cells

  2002cites this paper
• Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2

  2002cites this paper
• Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer

  2002cites this paper
• Cytotoxicity issues pertinent to lipoplex‐mediated gene therapy in‐vivo

  2002influential citation
• Gene Therapy of Lymphoma

  2002cites this paper
• A Lipid-based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex

  2002cites this paper
• Cell membranes as barriers for the use of antisense therapeutic agents.

  2002cites this paper
• Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy.

  2002cites this paper
• Targeted delivery of antisense oligonucleotides in cancer.

  2001cites this paper
• Cationic liposomes and nucleic acids

  2001cites this paper
• Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells.

  2001cites this paper